Introduction
============

Maternal immune activation (MIA) during pregnancy increases the risk of developing several mental disorders, including autism and schizophrenia ([@b1-mmr-18-04-3834]). Epidemiological studies have provided compelling evidence that perinatal factors such as MIA increase the risk of schizophrenia and associated disorders following prenatal maternal exposure to infection or inflammation ([@b2-mmr-18-04-3834],[@b3-mmr-18-04-3834]). To replicate such risks in animal models, fetuses can be exposed to MIA by administering viral mimetic double-stranded RNA polyriboinosinic-polyribocytidylic acid \[poly(I:C)\], a pro-inflammatory cytokine inducer, to pregnant females ([@b2-mmr-18-04-3834],[@b4-mmr-18-04-3834]). Notably, a broad range of behavioral impairments in rodent offspring due to gestational immune activation have been commonly described in schizophrenia patients, including deficits in prepulse inhibition (PPI) of acoustic startle response (ASR) ([@b5-mmr-18-04-3834],[@b6-mmr-18-04-3834]) and social interaction ([@b6-mmr-18-04-3834]), as well as brain abnormalities ([@b7-mmr-18-04-3834]). Among the behavioral outcomes investigated following prenatal immune treatment, PPI is considered as an operational measure of sensorimotor gating. Its deficit has been observed in acute/chronic patients with schizophrenia ([@b8-mmr-18-04-3834],[@b9-mmr-18-04-3834]) and PPI deficit in schizophrenia patients has been well documented ([@b9-mmr-18-04-3834],[@b10-mmr-18-04-3834]).

Through experimental investigation, the MIA model has provided substantial evidence of psychosis-associated dysfunction in schizophrenia. Psychosis-associated behavioral abnormalities in adult life have etiological significance in the neurodevelopmental perspective of schizophrenia ([@b5-mmr-18-04-3834],[@b11-mmr-18-04-3834],[@b12-mmr-18-04-3834]). A previous study demonstrated that treatment with the typical antipsychotic medication clozapine and the atypical antipsychotic haloperidol reverse cognitive impairment in MIA offspring ([@b6-mmr-18-04-3834]). The effects of maternal treatment with certain drugs on MIA offspring have also been observed; clozapine, haloperidol, risperidone, paliperidone and fluoxetine have exhibited protective effects against the emergence of behavioral and structural abnormalities in MIA offspring ([@b13-mmr-18-04-3834],[@b14-mmr-18-04-3834]). It has been reported that long-term administration of clozapine improves cognitive performance in poly(I:C)-induced MIA mice ([@b14-mmr-18-04-3834]). In addition, treatment with risperidone was reported to prevent the majority of neuropathological alterations in a peri-adolescent MIA mouse model ([@b13-mmr-18-04-3834]). Results from our previous study also demonstrated that MIA induces abnormal behavior associated with alterations in neurodevelopmental protein expression level in the offspring ([@b15-mmr-18-04-3834]).

*Panax ginseng* C.A. Meyer (PG) is one of the most important medicinal plants in Asia ([@b16-mmr-18-04-3834]). In an experimental brain injury model, PG can suppress microglial activation induced by lipopolysaccharide and improve the recovery of motor function after spinal cord injury, thus providing neuroprotection by alleviating post-traumatic inflammatory responses ([@b16-mmr-18-04-3834],[@b17-mmr-18-04-3834]). Experimental evidence has suggested that it can improve neurotransmission in the brain as an important pharmacological effect of PG ([@b16-mmr-18-04-3834],[@b17-mmr-18-04-3834]). Ginseng and its constituents are known to have beneficial effects on cognitive performance, memory, and neurodegenerative disease ([@b18-mmr-18-04-3834]). A number of previous studies have focused on the effects of ginseng on central nervous system diseases such as Alzheimer\'s disease, Parkinson\'s disease and depression ([@b19-mmr-18-04-3834],[@b20-mmr-18-04-3834]). However, few studies have investigated the effects of ginseng on schizophrenia. Chen and Hui ([@b21-mmr-18-04-3834]) observed that ginseng has the therapeutic potential to treat various neurological diseases including schizophrenia. Our previous study has also suggested that oral administrated PG can reduces the incidence of schizophrenia-like symptoms in a neurodevelopmental animal model induced by prenatal stress ([@b22-mmr-18-04-3834]).

The aim of the present study was to examine the effects of PG on behavioral abnormalities relevant to schizophrenia in MIA-induced mouse model offspring. It focused on two aspects: First, the manifestation of behavioral symptoms in a MIA model. Second, the influence of PG on expression levels of neurodevelopmental proteins in medial prefrontal cortex (mPFC) of a MIA model. The potential beneficial effects of PG on MIA offspring were examined based on schizophrenia-like behavior and protein levels in mPFC.

Materials and methods
=====================

### Preparation of PG extracts

Dried roots of PG were purchased from a local farm in Yunpung (Chungbuk, Republic of Korea). The root specimens were taxonomically identified by an Oriental medicine physician at the National Institute of Horticultural & Herbal Science, Rural Development Administration (Jeonju, Korea). A voucher specimen (HPR-207) was deposited in the herbarium of Herbal Crop Research Institute (Eumsung, Korea). The majority of traditional Oriental herbal materials are decocted with boiling water. Therefore, water extraction was used in the present study. In addition, ginsenosides are more soluble in water than in organic solvents ([@b17-mmr-18-04-3834]). Briefly, crushed PG materials (200 g) were extracted under reflux with distilled water three times. Water extracts were then combined and lyophilized. The yield was 18.3% (wt/wt) for PG in a dried state. Extracts were stored at −20°C until use.

### Animals

A total of 27 C57BL6/J mice (9 male and 18, female; 18--25 g) were purchased from Daehan BioLink Co., Ltd. (Eumseong, Korea). At the age of 8 weeks, the mice were mated in groups of one male with two females. When a vaginal plug was observed during daily checks, female mice were considered pregnant and mice were separated. All animals were housed under standard conditions (21±3°C and 40% humidity) in a 12-h light/dark cycle and had free access to food and water. All animal procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health ([@b23-mmr-18-04-3834]). Experimental procedures were approved by the Institutional Animal Care and Use Committee of Soonchunhyang University (approval no. SCH16-0063; Cheonan).

### MIA and drug administration

Pregnant female mouse were single injected on gestation day 9 (GD9) about 200 µl of poly(I:C) (n=12; potassium salt; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) or saline (n=6) solution via intravenous route at the tail vein under mild physical constraint. Poly(I:C) was dissolved in isotonic 0.9% NaCl solution to obtain desired dosage \[5 mg/kg; calculated based on pure form poly(I:C)\] ([@b15-mmr-18-04-3834]). All animals were returned to their cages immediately following the injection and left undisturbed until the weaning of the offspring. Powdered PG extracts were dissolved in water and orally administered (300 mg/kg/day) on postnatal day 35 for \~4 weeks, until postnatal day 65 ([@b24-mmr-18-04-3834]). All groups contained litters of 8 to 15 pups with similar numbers of males and females. Extremely large or small litters were eliminated. The offspring were weaned at 21 days and group-housed. Male offspring (n=41) were selected and used for further experiments. Three experimental groups were tested as adults: i) 'Control' (n=14) group animals were offspring of unstressed mothers; ii) Poly I:C injected group 'MIA' (n=13 male offspring) animal were offspring of mothers subjected to stress before parturition; and iii) PG group (n=14 male offspring) animals were those subjected to injection of Poly I:C followed by PG administration.

### Behavioral tests

Behavioral testing was performed when offspring reached 10 weeks of age (n=10--12/group; ≥2 pups/litter from each group). Only male subjects were included. The number of subjects in each of the three experimental groups was 10 (at least two pups per litter).

### PPI

An automated Startle Reflex System (SR-LAB; San Diego Instruments, Inc., San Diego, CA, USA) was used to measure PPI (n=10--12 animals/group). This system consisted of a startle chamber housed in a sound attenuated isolation cabinet equipped with an internal fan and light. A cylindrical transparent acrylic holding apparatus resting on a four-pegged platform within the isolation chamber was used to hold each subject throughout the testing session. Background noise and acoustic stimuli were controlled through the SR-LAB microcomputer and interface assembly. Stimuli were delivered through a speaker that was mounted above the cylindrical holding apparatus. All test chambers were located in a sound attenuated experimental room to minimize external noise, as previously described ([@b25-mmr-18-04-3834]). Background noise was present throughout the test session at 68 dB. Following a 5 min acclimation period to background noise, trials were presented in a pseudorandom order, including: i) 14 pulse-alone trials, in which a 40 msec, 120 dB broadband noise burst was presented; ii) 30 prepulse + 30 pulse trials, in which a 20 msec broadband noise prepulse at intensities of 3, 6 and 12 dB were applied above the background noise (10 trials at each intensity) preceded the onset of the 120 dB pulse for 100 msec; and iii) 8 non-stimulus trials comprising background noise only. The prepulse intensities used in the protocol did not induce a startle reaction. All trials were presented with an average intertrial interval of 22 sec (range, 15--30 sec). Additionally, four 120 dB pulse trials were presented at the beginning and the end of the test session, with a series of 60 acoustic stimuli trials. However, they were not used for the calculation of PPI values. Holding chambers were cleaned with 75% ethanol between test sessions. PPI values were calculated as a percentage score for each prepulse using the following formula: PPI (%)=100-\[(ASR for prepulse+pulse trial)/(ASR for pulse alone trial)\] ×100 ([@b25-mmr-18-04-3834]). Mean %PPI was used as an overall measure of the observed treatment for which percentage PPI data were averaged for three prepulses ([@b14-mmr-18-04-3834],[@b15-mmr-18-04-3834]).

### Forced-swim test (FST)

FST was performed as described previously ([@b26-mmr-18-04-3834],[@b27-mmr-18-04-3834]). Mice (n=10--12 animals/group) were gently placed in a large transparent cylinder filled with fresh tap water (25±2°C) for 5 min; water was changed between mice. The swimming, climbing and immobility behaviors were recorded with a video camera and by an observer with a stopwatch. The predominant behaviors were counted every 5 sec. Test scores for swimming (horizontal movement throughout the chamber and crossing quadrants), climbing (upward-directed movements up the side of the chamber and jump-ups from the bottom of the chamber) and immobility (no additional activity other than keeping the head above water or tiny whip kicks) behaviors were recorded.

### Open field test (OFT)

OFT was conducted to assess exploratory activity and reactivity to a novel environment. Mice (n=10--12 animals/group) were removed from their cages and placed individually in the center zone (17×17 cm) of the open field arena (50×50 cm) for 20 min; The apparatus was constructed of opaque Polygal. No background noise was provided. The duration in the central zone and the frequency of entry into the central zone were used as indices for anxiety-like behaviors. The box was cleaned with 70% ethanol between tests to eliminate odors of other mice. The experimenter exited the room and the behavior of the mouse was recorded as described previously ([@b28-mmr-18-04-3834]).

### Social interaction test (SIT)

SIT was adapted from previous studies (n=10--12 animals/group) ([@b29-mmr-18-04-3834],[@b30-mmr-18-04-3834]). Their social interaction partners were the same-sex siblings with approximately the same body weight that resided in the same cage after weaning. The room in which the chamber was located was darkened during testing and the chamber was illuminated with a single 25 W red light bulb placed \~100 cm above the base of the chamber. Each session lasted 20 min. Total duration of social play and the number and types of interactions were scored.

### Western blot

mPFC tissues (n=5--6 animals/group; \~0.5 mg/ml) were lysed in radioimmunoprecipitation assay buffer containing protease inhibitors (cat. no. EBA-1149; ELPIS-Biotech, Inc., Daejeon, Korea) and centrifuged at 18,341 × g for 10 min at 4°C. The Bradford assay was used to determine protein concentration. Proteins (80 µg/lane) were subjected to 10 and 12% SDS-PAGE and subsequently transferred to polyvinylidene difluoride membranes (Merck KGaA, Darmstadt, Germany). Membranes were blocked with 5% skimmed milk at room temperature for 1 h and subsequently probed with anti-dihydropyrimidinase-related 2 (Dpysl2; 1:1,000; cat. no. 9393; Cell Signaling Technology, Inc., Danvers, MA, USA), anti-LIM and SH3 domain 1 (Lasp1; 1:2,000; cat. no. MAB8991; Merck KGaA), anti-neurofilament medium (Nefm; 1:1,000; cat. no. 2838; Cell Signaling Technology, Inc.), anti-discs large homolog 4 (Dlg4; 1:1,000; cat. no. 3450; Cell Signaling Technology, Inc.) or anti-β-actin (Actb; 1:1,000; cat. no. sc-81178; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) antibodies overnight at 4°C. Following washing with 1× TBST, these membranes were incubated with horseradish peroxidase-conjugated secondary anti-mouse (1:10,000; cat. no. A9044; Sigma-Aldrich; Merck KGaA) or anti-rabbit (1:5,000; cat. no. LF-SA8002; Abfrontier; Adipogen AG, Liestal, Switzerland) for 1 h at room temperature. Immunoreactive bands were detected using an Enhanced Chemiluminescence kit (ELPIS-Biotech, Inc.). Quantitative measurements of Dpysl2, Lasp1, Nefm, Dlg4 and Actb protein expression levels were made using ImageJ software version 1.51k (National Institutes of Health, Bethesda, MD, USA; <http://imagej.nih.gov/ij>).

### Immunohistochemistry

Mice were deeply anesthetized with ethyl ether and perfused with 4% paraformaldehyde at room temperature for ≥30 min. Fixed brains were removed, frozen and sectioned (30 µm; n=4--5 animals/group). Frozen mPFC sections were blocked with normal horse serum (cat. no. S-2000; Vector Laboratories, Inc., Burlingame, CA, USA) for 1 h at room temperature and subsequently incubated with anti-Dpysl2 (1:700; cat. no. HPA002381; Atlas Antibodies AB, Stockholm, Sweden), anti-Nefm (1:100; cat. no. 2838; Cell Signaling Technology, Inc.) or anti-neuronal nuclei (NeuN; 1:100; cat. no. MAB377; Merck KGaA) antibodies overnight at 4°C. Following incubation, sections were incubated with Cy3-conjugated anti-rabbit (1:500; cat. no. 715-545-151; Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) and anti-mouse (1:800; cat. no. 111-165-003, Jackson ImmunoResearch Laboratories, Inc.) secondary antibodies at room temperature for 1 h. Fluorescent images were captured using a confocal laser-scanning microscope (FV10i; Olympus Corporation, Tokyo, Japan). Images were quantified with ImageJ software (National Institutes of Health, Bethesda, MD, USA) version 1.51k using a previously described protocol ([@b31-mmr-18-04-3834]).

### High-performance liquid chromatography (HPLC) analysis of ginsenosides

Analyses of ginsenosides Rb1, Rc, Rd, Re and Rf on 10 mg extract were conducted using a reverse-phase HPLC system in room temperature. HPLC chromatograms were recorded with a Waters 1525 Binary HPLC pump equipped with a Waters 2489 UV/VIS detector (Waters, Miami, FL, USA). Chromatographic separation was performed using a SunFire C-18 column (2.1×50 mm; 5 µm; Waters) with a mobile phase consisting of water (solvent A) and acetonitrile (solvent B). A gradient elution was used and the ratio of these solvents was as follows: 95:5 (A:B) at 0 min, 65:35 (A:B) at 35 min, and 20:80 (A:B) at 40 min. UV detection was set at 204 nm. All injections were conducted three times. The injection volume was 10 µl and the flow rate was set at 1.0 ml/min.

### Statistical analysis

All data were expressed as the mean ± standard error of the mean. Data were assessed with one-way analysis of variance (ANOVA) followed by Tukey\'s post-hoc test. All statistical analyses were performed using SPSS software version 21 (IBM Corp., Armonk, NY, USA). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### PPI

We tested whether PG treatment to effective in preventing emergence of sensorimotor gating deficiency following MIA during adulthood. To determine the effects of PG on sensorimotor gating function, we measured acoustic startle response (ASR) and performed PPI analysis for Control, MIA-induced PPI disrupted mice and PG treated MIA mice. One-way analysis of variance showed significant effects of PG. It decreased ASR and reversed MIA-induced PPI disruption as shown in [Fig. 1](#f1-mmr-18-04-3834){ref-type="fig"}. MIA significantly (P\<0.05) increased the acoustic startle amplitude at 120 dB compared with control group mice ([Fig. 1A](#f1-mmr-18-04-3834){ref-type="fig"}). PPI values were not significantly reduced (P\>0.05) at 71, 74 and 80 dB following MIA alone compared to those in the control ([Fig. 1B](#f1-mmr-18-04-3834){ref-type="fig"}). The MIA-induced PPI disruption in 120 dB pulse stimulus trials ([Fig. 1A](#f1-mmr-18-04-3834){ref-type="fig"}) was consistently seen across all prepulse levels, leading to significant (P\<0.05) decreases in the mean percent PPI in MIA offspring compared with the control group ([Fig. 1C](#f1-mmr-18-04-3834){ref-type="fig"}). This indicated that MIA induced sensorimotor gating deficits. Moreover, MIA-induced PPI disruption was significantly (P\<0.05) improved by treatment with PG. This indicated that PG treatment group animals recovered sensorimotor gating deficits from MIA-induced PPI disruption (P\<0.05).

### Forced swim test

There were significant differences in result of FST among Control, MIA and PG treated MIA groups ([Table I](#tI-mmr-18-04-3834){ref-type="table"}). Total duration of immobility in MIA offspring was significantly (P\<0.05) increased compared to that in the control. Changed Behavior were significantly (P\<0.05) recovered after PG-treated MIA mice, compared with the untreated MIA group mice (P\<0.05). Each behavior shown that total duration of swimming and climbing decrease in MIA group mice compared with the control and PG treatment groups (P\<0.05).

### Open-field test

The number of central entries, line crossings and grooming, and number and duration of cage sniffing behaviors in the MIA group were significantly decreased (P\<0.05) compared with those in the control. However, these scores were reversed (P\<0.05) to normal levels following PG treatment ([Table II](#tII-mmr-18-04-3834){ref-type="table"}). The number and duration of immobility behaviors in the MIA group significantly increased (P\<0.05) compared with the control. These scores were also recovered (P\<0.05) to normal levels following PG treatment and indicated a recovery from depression behavior ([Table II](#tII-mmr-18-04-3834){ref-type="table"}).

### SIT

Severe social deficits were induced in the MIA offspring ([Table III](#tIII-mmr-18-04-3834){ref-type="table"}). The number and duration of cage sniffing and following, in the MIA group were significantly decreased (P\<0.05) compared with the control ([Table III](#tIII-mmr-18-04-3834){ref-type="table"}). These scores were increased to control levels following treatment with PG. However, aggressive behaviors (for example, fighting and aggressive grooming, including grooming to the neck), excluding biting, during SIT were significantly increased (P\<0.05) in the MIA group compared with the control group ([Table III](#tIII-mmr-18-04-3834){ref-type="table"}). These scores were decreased to levels observed in the control group following treatment with PG. These results indicated that MIA-induced social interaction impairment was reversed by PG treatment.

### Western blot and immunohistochemistry

The expression of neurodevelopmental proteins was altered in the mPFCs of mice prenatally exposed to poly(I:C). To determine whether neurodevelopmental proteins such as Nefm, Lasp1, Dpysl2 and Dlg4 were downregulated in MIA offspring, western blot analyses were performed. The results revealed that the expression levels of these four proteins in the mPFC were significantly decreased in the MIA group, compared with Control mice ([Fig. 2](#f2-mmr-18-04-3834){ref-type="fig"}). The MIA-induced reduction in protein expression levels was significantly restored (P\<0.05) following PG treatment. ([Fig. 2](#f2-mmr-18-04-3834){ref-type="fig"}). Immunohistochemical analyses of mPFC sections revealed that Nefm and Dpysl2 protein expressions were significantly reduced (P\<0.05) in MIA mice compared with mice in the control group ([Figs. 3](#f3-mmr-18-04-3834){ref-type="fig"} and [4](#f4-mmr-18-04-3834){ref-type="fig"}, respectively), and treatment with PG significantly increased Nefm and Dpysl2 expression compared with untreated MIA mice (both P\<0.05). These results indicated that PG treatment significantly altered the expression of neurodevelopmental proteins in MIA offspring.

### Detection of major ginsenosides

Major ginsenosides, including Rb1, Rc, Rd, Re and Rf of ginseng were detected by HPLC ([Fig. 5](#f5-mmr-18-04-3834){ref-type="fig"}). Among the major ginsenosides, ginsenoside Rc was the most abundant in ginseng samples. Ginsenoside Rc is considered the main ginsenoside that contributes to the antioxidant activities of ginseng. Ginsenoside Rc was shown to induce the overexpression of catalase, which inhibited the production of reactive oxygen species in human embryonic kidney 293T (HEK293T) cells ([@b32-mmr-18-04-3834]).

Discussion
==========

In the present study, it was determined that exposure to MIA resulted in schizophrenia-like behaviors, including impaired sensorimotor gating, decreased PPI and increased startle sensitivity in adult mouse offspring. MIA-induced behavioral impairments were reversed by PG treatment. Western blot and immunohistochemical analyses of the mPFC revealed that several neurodevelopmental proteins were downregulated in MIA offspring compared with the control group, with PG treatment inhibiting this downregulation. To the best of our knowledge, this is the first report to demonstrate that PG treatment reduced behavioral alterations and increased neurodevelopmental protein expression in an MIA-induced animal model of schizophrenia.

A limited number of studies have demonstrated the potential efficacy of the antipsychotics haloperidol and clozapine, or the antidepressant fluoxetine in preventing the onset of psychotic symptoms in a MIA-induced animal model of schizophrenia at GD9 ([@b14-mmr-18-04-3834]). It has been reported that PG exerts similar effects to antipsychotic and antidepressant drugs ([@b22-mmr-18-04-3834],[@b33-mmr-18-04-3834]).

Ginseng has been demonstrated to have complex pharmacological activities against significant psychiatric symptoms, including sleep disorder, pressure of speech, euphoria, agitation, psychosis, confusion and depression ([@b34-mmr-18-04-3834],[@b35-mmr-18-04-3834]). *Panax vietnamensis* has significant and potentially useful psychopharmacological effects: It increases spontaneous locomotor activity, enhances stress endurance, reduces anxiety-like behavior and ameliorates scopolamine-induced memory impairments in mice ([@b36-mmr-18-04-3834]).

Crucial components of PG have been reported to possess neuroprotective effects ([@b37-mmr-18-04-3834]) that may decrease psychiatric symptoms ([@b20-mmr-18-04-3834]). In addition, previous studies have revealed that component from ginseng extract may have psychotropic effects and improve agonistic behavior in a mouse model ([@b38-mmr-18-04-3834],[@b39-mmr-18-04-3834]). Psychotropic actions, including aggressive episodes (offensive sideways posture and attack bite) ([@b38-mmr-18-04-3834]) and maternal aggression ([@b39-mmr-18-04-3834]) in mice are significantly suppressed by ginseng. A previous study reported that *Panax quinquefolius* is an effective treatment against negative and cognitive symptoms in both acute and chronic animal models of psychosis ([@b40-mmr-18-04-3834]). Our previous study demonstrated that PG extract significantly reduces prenatal stress-induced psychiatric symptoms in an animal model ([@b22-mmr-18-04-3834]). Results from the present study suggested that PG may be considered as a candidate to treat several symptoms of schizophrenia, based on the effects observed in the adult offspring of mice treated with poly(I:C).

A number of previous studies have suggested that impaired PPI of the startle response in patients with schizophrenia, as well as in animal models, may reflect sensorimotor gating disruption ([@b9-mmr-18-04-3834],[@b14-mmr-18-04-3834]). The present study demonstrated that MIA-induced PPI deficits were markedly reversed by PG. Meyer *et al* ([@b14-mmr-18-04-3834]) reported the effects of atypical antipsychotic drug administration on PPI deficit in a mouse model of schizophrenia. Moreover, impaired social interaction behavior was observed in MIA mice ([@b14-mmr-18-04-3834]). In particular, MIA may lead to negative and cognitive symptoms of schizophrenia ([@b41-mmr-18-04-3834],[@b42-mmr-18-04-3834]), including social withdrawal, cognitive dysfunction and anhedonia; in addition, MIA may cause behavioral deficits in adulthood ([@b41-mmr-18-04-3834],[@b42-mmr-18-04-3834]). The results of the present study supported previous findings that demonstrated that prenatal poly(I:C)-induced MIA in mice is capable of inducing aggressive behaviors ([@b41-mmr-18-04-3834]). In the present study, the MIA-induced decrease in non-aggressive behaviors was inhibited by oral treatment with PG. In addition, certain behavioral patterns observed in the FST and OFT that indicated depressive behaviors were prevented by PG treatment.

The expression levels of Nefm, Lasp1, Dlg4 and Dpysl2 proteins were also determined in the present study. The results indicated that application of MIA during crucial periods of fetal brain development resulted in alterations in neurodevelopmental protein expression, including Nefm, Lasp1, Dlg4 and Dpysl2. Dpysl2, a microtubule-binding protein, has structural and regulatory roles in cytoskeletal dynamics, vesicle trafficking and synaptic transmission in the developing brain ([@b43-mmr-18-04-3834],[@b44-mmr-18-04-3834]). Furthermore, altered Dpysl2 activity has been associated with schizophrenia in animal models, and Dpysl2 gene polymorphisms are associated with schizophrenia susceptibility in humans ([@b45-mmr-18-04-3834],[@b46-mmr-18-04-3834]). However, additional research is required to determine the causal link between the effects of PG and reduced schizophrenia-like behaviors. Nevertheless, the present study demonstrated that PG has the potential to be used as a natural alternative remedy for various psychological disorders.

In conclusion, PG and/or its components may be a useful treatment option for schizophrenia. Inhibition of psychotic symptoms may be achieved though the pharmacological effects of PG.
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![Modulation of PPI and acoustic startle response by PG treatment in MIA mice. (A) Startle amplitude was calculated to 120dB of alone stimuli in total performed trials. (B) Inhibition of startle reflex to a 120 dB stimulus. A stimulus was achieved through prepulses of 71, 74 and 80 dB, corresponding to 3, 6 and 12 dB above background noise, respectively. (C) PPI is presented as a mean PPI percentage value in startle amplitude as a function of the magnitude of prepulse stimulus. Data are presented as the mean ± standard error of the mean; \*P\<0.05 vs. CON; ^\#^P\<0.05 vs. MIA. CON, control group; MIA, maternal induced activation group; PG, *Panax ginseng*-treated MIA group; PPI, prepulse inhibition.](MMR-18-04-3834-g00){#f1-mmr-18-04-3834}

![Protein expression levels of Nefm, Lasp1, Dpysl2 and Dlg4 in the medial prefrontal cortex of MIA-induced mice. (A) Protein expression levels were determined by western blot analysis; Actb was used as an internal control. Nefm, Lasp1, Dpysl2 and Dlg4 expressions were decreased in the MIA group compared with CON, and treatment with PG inhibited this decrease. (B-E) Quantitative analysis of (B) Dpysl2, (C) Lasp1, (D) Nefm and (E) Dlg4 expression. Data are presented as the mean ± standard error of the mean. \*P\<0.05 vs. CON; ^\#^P\<0.05 vs. MIA. Actb, β-actin; CON, control group; Dlg4, discs large MAGUK scaffold protein 4; Dpysl2, dihydropyrimidinase like 2; Lasp1, LIM and SH3 protein; MIA, maternal induced activation group; Nefm, neurofilament M; PG, *Panax ginseng*-treated MIA group.](MMR-18-04-3834-g01){#f2-mmr-18-04-3834}

![Immunohistochemical analysis of Nefm expression in the medial prefrontal cortex of MIA-induced mice. (A) Confocal microscopy of Nefm immunofluorescent staining (secondary anti-mouse, green; Alexa Fluor 488); nuclei were stained with DAPI (blue). Treatment with PG inhibited this decrease. (B) Quantitative analysis of Nefm expression revealed a significant decrease of Nefm expression in the MIA group compared with CON. Scale bar, 50 µm. Data are presented as the mean ± standard error of the mean; \*P\<0.05 vs. CON; ^\#^P\<0.05 vs. MIA. CON, control group; MIA, maternal induced activation group; Nefm, neurofilament M; PG, *Panax ginseng*-treated MIA group.](MMR-18-04-3834-g02){#f3-mmr-18-04-3834}

![Immunohistochemical analysis of Dpysl2 expression in the medial prefrontal cortex of MIA-induced mice. (A) Confocal microscopy of Dpysl2 immunofluorescent staining for Dpysl2 (secondary anti-rabbit, red; Cy3) with NeuN (secondary anti-mouse, green; Alexa Fluor 488). Scale bar, 50 µm. (B) Quantitative analysis of Dpysl2 expression revealed a decrease of Dpysl2 expression in the MIA group compared with CON, and treatment with PG inhibited this decrease. Data are presented as the mean ± standard error of the mean; \*P\<0.05 vs. CON; ^\#^P\<0.05 vs. MIA. CON, control group; Dpysl2, dihydropyrimidinase like 2; MIA, maternal induced activation group; NeuN, anti-neuronal nuclei; PG, *Panax ginseng*-treated MIA group.](MMR-18-04-3834-g03){#f4-mmr-18-04-3834}

![High-performance liquid chromatography of the major ginsenosides, including Rb1, Rc, Rd, Re and Rf.](MMR-18-04-3834-g04){#f5-mmr-18-04-3834}

###### 

Behavior of CON, MIA and PG mice in the forced swim test.

  Behavior         CON           MIA                                                          PG
  ---------------- ------------- ------------------------------------------------------------ ------------------------------------------------------------
  Swimming (n)     33.86±1.35    21.57±1.31^[a](#tfn1-mmr-18-04-3834){ref-type="table-fn"}^   33.71±0.71^[b](#tfn2-mmr-18-04-3834){ref-type="table-fn"}^
  Climbing (n)     18.57±1.70    10.43±0.48^[a](#tfn1-mmr-18-04-3834){ref-type="table-fn"}^   14.86±0.96^[b](#tfn2-mmr-18-04-3834){ref-type="table-fn"}^
  Immobility (n)     7.57±1.39   28.00±1.00^[a](#tfn1-mmr-18-04-3834){ref-type="table-fn"}^   11.43±0.90^[b](#tfn2-mmr-18-04-3834){ref-type="table-fn"}^

P\<0.05 vs. CON

P\<0.05 vs. MIA; data are presented as the mean ± standard error of the mean. CON, control group; MIA, maternal induced activation group; n, number of occurrences of the behavior (number calculated every 5 sec); PG, *Panax ginseng*-treated MIA group.

###### 

Behavior of CON, MIA and PG mice in the open field test.

  Behavior              CON            MIA                                                            PG
  --------------------- -------------- -------------------------------------------------------------- --------------------------------------------------------------
  Central entered (n)   42.29±6.11     15.57±1.31^[a](#tfn3-mmr-18-04-3834){ref-type="table-fn"}^     29.57±4.72^[b](#tfn4-mmr-18-04-3834){ref-type="table-fn"}^
  Line cross (n)        22.00±4.04     5.00±1.02^[a](#tfn3-mmr-18-04-3834){ref-type="table-fn"}^      12.29±4.86^[b](#tfn4-mmr-18-04-3834){ref-type="table-fn"}^
  Run (n)               0.00±0.00      0.00±0.00                                                      0.43±0.79
  Run (sec)             0.00±0.00      0.00±0.00                                                      0.43±0.79
  Rear (n)              96.14±12.47    74.71±6.15                                                     69.14±23.41
  Rear (sec)            149.57±9.97    126.86±8.84                                                    122.86±35.59
  Grooming (n)          11.43±2.86     3.43±0.57^[a](#tfn3-mmr-18-04-3834){ref-type="table-fn"}^      15.71±3.64^[b](#tfn4-mmr-18-04-3834){ref-type="table-fn"}^
  Grooming (sec)        63.14±2.73     43.00±11.01                                                    47.86±10.57
  Cage sniff (n)        106.43±18.76   62.86±4.97^[a](#tfn3-mmr-18-04-3834){ref-type="table-fn"}^     181.71±30.34^[b](#tfn4-mmr-18-04-3834){ref-type="table-fn"}^
  Cage sniff (sec)      221.57±36.15   123.71±13.79^[a](#tfn3-mmr-18-04-3834){ref-type="table-fn"}^   381.86±77.10^[b](#tfn4-mmr-18-04-3834){ref-type="table-fn"}^
  Immobile (n)          3.14±1.06      25.57±3.14^[a](#tfn3-mmr-18-04-3834){ref-type="table-fn"}^     0.29±0.76^[b](#tfn4-mmr-18-04-3834){ref-type="table-fn"}^
  Immobile (sec)        12.86±6.61     89.43±11.72^[a](#tfn3-mmr-18-04-3834){ref-type="table-fn"}^    0.43±1.13^[b](#tfn4-mmr-18-04-3834){ref-type="table-fn"}^

P\<0.05 vs. CON

P\<0.05 vs. MIA; data are presented as the mean ± standard error of the mean. CON, control group; MIA, maternal induced activation group; n, number of behavior observed; PG, *Panax ginseng*-treated MIA group.

###### 

Behavior of CON, MIA and PG mice in social interaction test.

  Behavior           CON          MIA                                                          PG
  ------------------ ------------ ------------------------------------------------------------ ------------------------------------------------------------
  Sniffing (n)       50.43±6.28   21.86±2.12^[a](#tfn5-mmr-18-04-3834){ref-type="table-fn"}^   43.71±1.96^[b](#tfn6-mmr-18-04-3834){ref-type="table-fn"}^
  Sniffing (sec)     81.29±8.20   38.43±5.06^[a](#tfn5-mmr-18-04-3834){ref-type="table-fn"}^   80.86±8.04^[b](#tfn6-mmr-18-04-3834){ref-type="table-fn"}^
  Following (n)      7.86±1.28    4.57±0.61^[a](#tfn5-mmr-18-04-3834){ref-type="table-fn"}^    11.71±2.21^[b](#tfn6-mmr-18-04-3834){ref-type="table-fn"}^
  Following (sec)    16.86±2.34   8.00±0.90^[a](#tfn5-mmr-18-04-3834){ref-type="table-fn"}^    28.00±6.11^[b](#tfn6-mmr-18-04-3834){ref-type="table-fn"}^
  Grooming (n)       1.71±0.36    1.00±0.65                                                    3.86±0.70^[b](#tfn6-mmr-18-04-3834){ref-type="table-fn"}^
  Grooming (sec)     7.00±1.72    3.29±2.15                                                    15.14±2.63^[b](#tfn6-mmr-18-04-3834){ref-type="table-fn"}^
  Fight (n)          0.29±0.18    1.29±0.18^[a](#tfn5-mmr-18-04-3834){ref-type="table-fn"}^    0.14±0.14^[b](#tfn6-mmr-18-04-3834){ref-type="table-fn"}^
  Fight (sec)        0.43±0.30    4.57±1.00^[a](#tfn5-mmr-18-04-3834){ref-type="table-fn"}^    0.57±0.57^[b](#tfn6-mmr-18-04-3834){ref-type="table-fn"}^
  Aggressive (n)     0.29±0.18    1.71±0.42^[a](#tfn5-mmr-18-04-3834){ref-type="table-fn"}^    0.14±0.14^[b](#tfn6-mmr-18-04-3834){ref-type="table-fn"}^
  Aggressive (sec)   1.14±0.77    6.29±2.01^[a](#tfn5-mmr-18-04-3834){ref-type="table-fn"}^    0.29±0.29^[b](#tfn6-mmr-18-04-3834){ref-type="table-fn"}^
  Biting (n)         0.29±0.18    1.00±0.49                                                    1.29±0.52
  Biting (sec)       0.29±0.18    2.43±1.17                                                    1.57±0.57

P\<0.05 vs. CON

P\<0.05 vs. MIA; data are presented as the mean ± standard error of the mean. CON, control group; MIA, maternal induced activation group; n, number of the behavior; PG, *Panax ginseng*-treated MIA group.
